Skip to content

Company · founded 1998

Oncovir (United States)

Washington D.C., United States · oncovir.com

Manage this page

Citations, last 5 years: 447
Works, last 5 years: 28
h-index: 75
Scientists listed: 1
Grants since 2016: 6

Grants received

2020–2023 · research · R44

Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas

George Yancey Gillespie · Oncovir (United States) · funded by National Institutes of Health

$1 625Virus-based gene therapy research

2020–2023 · research · R44

Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas

George Yancey Gillespie · Oncovir (United States) · funded by National Institutes of Health

$611.9kVirus-based gene therapy research

2020–2025 · research · R44

Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas

George Yancey Gillespie · Oncovir (United States) · funded by National Institutes of Health

$890.8kVirus-based gene therapy research

2020–2021 · research · R44

Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas

George Yancey Gillespie · Oncovir (United States) · funded by National Institutes of Health

$497.3kVirus-based gene therapy research

2016–2020 · research · R44

In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study

Andres Mario Salazar · Oncovir (United States) · funded by National Institutes of Health

$732.2k

2016–2018 · research · R44

In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study

Andres Mario Salazar · Oncovir (United States) · funded by National Institutes of Health

$732.2k